Pharmacogenetics – CYP2C19 Genetic Testing

Product detailed description

CYP2C19 genetic testing helps identify how your genetic makeup may influence the way your body processes certain medications. People can respond differently to the same drug – while a medication may work as expected for one person, another may experience reduced effectiveness or more pronounced side effects. Genetic differences in drug metabolism are one of the reasons behind these variations.

The test analyzes the CYP2C19 gene, which encodes an enzyme involved in the metabolism of several commonly prescribed medications. These include certain antidepressants, proton pump inhibitors used to reduce stomach acid, and the antiplatelet medication clopidogrel, which helps prevent blood clots.

Genetic variations in CYP2C19 may cause the body to metabolize certain medications more slowly or more rapidly. Depending on the drug, these differences can influence treatment effectiveness, drug concentrations, and the risk of adverse reactions. For some medications, CYP2C19 activity also affects conversion into the active form.

What does CYP2C19 genetic testing evaluate?

• Drug metabolism – genetic predispositions associated with slower or faster processing of certain medications.

• Medication effectiveness – genetic factors that may influence individual responses to specific drugs.

• Risk of side effects – variants associated with altered drug concentrations and adverse reactions.

• CYP2C19 pharmacogenetic profile – information that may help healthcare professionals personalize medication selection and dosing.

Who may benefit from CYP2C19 genetic testing?

• Individuals taking medications affected by CYP2C19 activity.

• Patients experiencing unexpected side effects or insufficient treatment response to certain medications.

• People who may be prescribed drugs whose effectiveness or metabolism depends on CYP2C19.

• Individuals interested in personalized medicine and pharmacogenetic testing.

What can the results reveal?

The CYP2C19 genetic test identifies the analyzed variants that may affect CYP2C19 enzyme activity. Depending on the scope of the analysis, results may allow prediction of an individual's metabolizer status, such as poor, intermediate, normal, rapid, or ultrarapid metabolizer.

This information may help healthcare professionals make more informed decisions about medication selection, dosage adjustments, and monitoring of treatment effectiveness or adverse effects.

Important: Genetic test results alone cannot determine the most appropriate medication or dosage. Drug response is also influenced by age, health conditions, liver function, and interactions with other medications. Any treatment changes should always be discussed with a qualified healthcare professional. This test does not replace medical care.